04/03/2021 6:42 pm Welcome to isteroids.com - BLOG

Thursday 10, Feb 2011

  Infliximab better than steroids for Crohn’s Therapy

Posted By
Pin it Share on Tumblr

Infliximab better than steroids for Crohn's TherapyIn a study with 129 patients, initial treatment with infliximab plus azathioprine in patients with moderate to severe Crohn’s disease leads to more remissions when compared to a standard approach starting with topical or systemic steroid treatment.

Geert D’Haens, M.D., said at the 13th United European Gastroenterology Week, “Steroids are not necessary for treating Crohn’s disease.”

The study was sponsored by Centocor and Schering-Plough.

Thursday 10, Feb 2011

  Infliximab helps Ulcerative Colitis Patients

Posted By
Pin it Share on Tumblr

Infliximab helps Ulcerative Colitis PatientsAccording to a review of more than 600 patients enrolled in two pivotal studies, patients with moderate to severe ulcerative colitis treated with infliximab had their colectomy rate cut by more than a third during the first year of treatment, compared with control patients.

Dr. Brian G. Feagan at the annual meeting of the American College of Gastroenterology said, “These are unique data that show we can alter the natural history of the disease.”

From Internalmedicinenews.com:

“It seems like infliximab may alter the natural course of UC by reducing the need for colectomy,” commented Dr. Miguel D. Regueiro, codirector of the inflammatory bowel disease center at the University of Pittsburgh. Physicians and patients will need to decide whether the risks and complications of colectomy are high or low compared with biologic therapy, and whether quality of life is better with colectomy or biologic therapy, he said.

UC patients “in remission with their colon have a better quality of life” than patients who undergo colectomy, commented Dr. Stephen B. Hanauer, professor of medicine and chief of gastroenterology at the University of Chicago. “Chronically sick patients benefit from cholectomy, but the goal of treatment is to get patients in remission and off steroids. Biologic treatments can do this,” he said in an interview.

The new analysis used data collected in the Active Ulcerative Colitis Trials 1 and 2 (ACT 1 and ACT 2), which together compared two dosages of infliximab (either 5 mg/kg or 10 mg/kg) with placebo in two different protocols that treated patients for as long as 54 weeks. The primary finding was that patients treated with either dosage were more likely than placebo patients to have a clinical response after 8, 30, and 54 weeks of treatment (N. Engl. J. Med. 2005;353:2462–76). This led to Food and Drug Administration approval of infliximab (Remicade) for treating moderately to severely active UC.

The ACT 1 and 2 studies were sponsored by Centocor Inc. that markets infliximab in the United States, and by Schering-Plough that markets the drug in all other countries.

Wednesday 02, Feb 2011

  Infliximab effective in treating active Ulcerative Colitis

Posted By
Pin it Share on Tumblr

Infliximab effective in treating active Ulcerative ColitisAccording to results of two multicenter phase III trials reported at the annual Digestive Disease Week, active ulcerative colitis responds to the drug infliximab.

Both studies showed that Infliximab is also effective in inducing remission and leads to mucosal healing in patients with active ulcerative colitis.

From Internalmedicinenews.com:

Both ACT 1 and 2 trials had similar results and patient populations, according to Dr. Sandborn, whose institution was one of 55 study centers. He described subjects as outpatients with relatively stable disease.

At enrollment, ACT 1 patients had not responded to treatment with corticosteroids and/or immunosuppressive therapy, whereas patients in ACT 2 had experienced treatment failure with 5-aminosalicylates, steroids, and/or immunosuppressives. The duration of ACT 1 also was longer (54 vs. 30 weeks).

Clinical response was defined as a decrease in the Mayo score of at least 30% and 3 or more points, plus either a reduction of 1 or more points in the rectal bleeding score or a score of 0 or 1 at week 8.

In addition to clinical response, both trials studied clinical remission—a Mayo score of 2 or less, with no individual subscores greater than 1—and mucosal healing, characterized as an endoscopy subscore of 0 or 1.

William Sandborn, M.D., principal investigator of ACT 2 and head of the Mayo Clinic College of Medicine‘s irritable bowel disease interest group and clinical research unit, said, “This is very encouraging news for a patient population that has few treatment options.”

Friday 05, Nov 2010

  Drug combination useful for remission in Crohn’s disease

Posted By
Pin it Share on Tumblr

drug-combination-useful-for-remission-in-crohns-diseaseA Mayo Clinic study has suggested that the combination of biologic therapy with immune-suppressing drugs first instead of the drugs alone can be more than just beneficial to prompt remission from Crohn’s disease in a better way.

The study was published in the April 15, 2010 issue of the New England Journal of Medicine.

The study results are worthwhile enough to initiate a change in clinical practice, according to William Sandborn, M.D., gastroenterologist and vice chair of the Division of Gastroenterology & Hepatology, Mayo Clinic, Rochester.

Wednesday 23, Jun 2010

  Ulcerative Colitis patients are better treated with Corticosteroids

Posted By
Pin it Share on Tumblr

Ulcerative Colitis patients are better treated with CorticosteroidsAbbott/Eisai’s Humira will be earning Gold Standard Status for Ulcerative Colitis in 2012, as per a new report from Decision Resources, one of the leading research and advisory firms worldwide for pharmaceutical and healthcare issues.

Decision Resources found that gastroenterologists were able to ascertain therapy effects on induction of remission, which has implications for researchers in moderation to severe ulcerative colitis.

It was remarked by Decision Resources Analyst Benjamin Guikema, Ph.D. that adalimumab is superior to infliximab in maintenance setting. The study revealed that corticosteroids have an advantage over Remicade for treating ulcerative colitis patients, suggesting role of steroids for good health.

Saturday 05, Jun 2010

  Stubborn Ulcerative Colitis can be treated with arthritis drug

Posted By
Pin it Share on Tumblr

Stubborn Ulcerative Colitis can be treated with arthritis drugInfliximab, a drug presently used for treating patients suffering with rheumatoid arthritis and Crohn’s diseases, can also be used to treat patients with stubborn cases of ulcerative colitis, a serious intestinal disorder.

It was remarked by review co-author Dr. Anthony Kwaku Akobeng that people with active ulcerative colitis and not responding to corticosteroids or immunosuppressive agents can be helped by infliximab as the drug can induce clinical response to promote mucosal healing and reducing need for colectomy, at least in the short term.

The review of studies appeared in an issue of The Cochrane Library, a publication of The Cochrane Collaboration, which is an international organization that evaluates medical research.

Thursday 20, May 2010

  Drug combination found effective for Crohn’s disease remission

Posted By
Pin it Share on Tumblr

Drug combination found effective for Crohn's disease remissionA study led by Mayo Clinic recently suggested that a combination of immune-suppressing drugs first instead of immune-suppressing drugs alone may prove useful for bringing remission from Crohn’s disease.

It was found that a combination of infliximab plus azathioprine allows more patients to achieve mucosal healing and remission than a therapy with azathioprine alone.

William Sandborn, M.D., gastroenterologist and vice chair of the Division of Gastroenterology & Hepatology, Mayo Clinic, Rochester, said that these results are good enough to change clinical practice.

The study was published in the April 15, 2010 issue of the New England Journal of Medicine.

Thursday 01, Apr 2010

  Corticosteroids superior to Remicade for stimulating remission

Posted By
Pin it Share on Tumblr

Corticosteroids superior to Remicade for stimulating remissionAbbott/Eisai’s Humira would be earning Gold Standard Status for Ulcerative Colitis in 2012 as per a new Report from Decision Resources, one of the leading research and advisory firms in the world for pharmaceutical and healthcare issues.

Decision Resources disclosed that gastroenterologists have been able to find out the effect of a therapy on remission induction, which is a critical attribute to influence researchers’ decision in moderation to severe ulcerative colitis.

It was remarked by Decision Resources Analyst Benjamin Guikema, Ph.D. that adalimumab is believed to be more effective than infliximab in terms of maintenance setting besides having a reduced risk of prominent organ toxicity. The finding is believed to add one more “feather” to benefits of steroids.

Wednesday 08, Jul 2009

  Improved Outlook for Crohn’s disease due to New Medical Therapies

Posted By
Pin it Share on Tumblr

Improved Outlook for Crohn’s disease due to New Medical TherapiesAccording to a recent study by the Mayo Clinic, administration of infliximab (Remicade) alone or in a combination with azathioprine may prove to be the most effective form of treatment than azathioprine alone for curing moderate to severe Crohn’s disease in patients.

Crohn’s disease is an inflammatory ailment of the human gastrointestinal tract that is believed to affect as much as 500,000 people in the United States alone. No definite cure has yet been discovered for this ailment.

In the past, patients suffering from this disease have been treated sequentially with some form of steroids followed by azathioprine and thereafter by monoclonal anti-bodies like infliximab.

However, infliximab-based medical strategies to cure Crohn’s disease are far more effective than treatment with azathioprine as per William Sandborn, M.D., the lead author and a gastroenterologist at Mayo Clinic.

This study is expected to create a new paradigm besides offering new, safer opportunities to patients suffering from Crohn’s disease when it comes to improving quality of life.